Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma, Renal Cell 2Advanced Cancer 2Unilateral Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

niraparib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unilateral Breast Neoplasms × abemaciclib × Clear all
NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

OHSU Knight Cancer Institute

Phase 1 Completed
8 enrolled
Breast

Unilateral Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡